Tamara L Lotan

List of Publications by Year
in descending order

187	10,767	50566	40945
papers	citations	48 h-index	97 g-index

194	194	194	12869
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up. European Urology Oncology, 2023, 6, 110-112.	2.6	3
2	High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer and Prostatic Diseases, 2023, 26, 105-112.	2.0	2
3	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. European Urology Oncology, 2022, 5, 113-117.	2.6	30
4	A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 659-665.	2.0	9
5	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. Cancer Immunology, Immunotherapy, 2022, 71, 943-951.	2.0	9
6	<scp>P2X4</scp> purinergic receptors offer a therapeutic target for aggressive prostate cancer. Journal of Pathology, 2022, 256, 149-163.	2.1	16
7	Clinical and genomic features of SPOPâ€mutant prostate cancer. Prostate, 2022, 82, 260-268.	1.2	20
8	Validation of Long Mononucleotide Repeat Markers for Detection of Microsatellite Instability. Journal of Molecular Diagnostics, 2022, 24, 144-157.	1.2	10
9	<scp>GPNMB</scp> expression identifies <scp>TSC1</scp>/2/<scp>mTOR</scp>â€associated and <scp>MiT</scp> family translocationâ€driven renal neoplasms. Journal of Pathology, 2022, 257, 158-171.	2.1	21
10	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. Molecular Cancer Research, 2022, 20, 527-541.	1.5	3
11	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer and Prostatic Diseases, 2022, 25, 713-719.	2.0	17
12	Health inequity drives disease biology to create disparities in prostate cancer outcomes. Journal of Clinical Investigation, 2022, 132, .	3.9	17
13	Germline BRCA2, ATM and CHEK2 alterations shape somatic mutation landscapes in prostate cancer.. Journal of Clinical Oncology, 2022, 40, 148-148.	0.8	0
14	Association of B7â€H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer, 2022, 128, 2269-2280.	2.0	16
15	Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.. Journal of Clinical Oncology, 2022, 40, 5025-5025.	0.8	3
16	Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.. Journal of Clinical Oncology, 2022, 40, 5012-5012.	0.8	4
17	Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.. Journal of Clinical Oncology, 2022, 40, 5015-5015.	0.8	3
18	De novo neuroendocrine features in prostate cancer. Human Pathology, 2022, 127, 112-122.	1.1	7

#	Article	IF	Citations
19	The prostate tissueâ€based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. Journal of Pathology: Clinical Research, 2022, 8, 481-491.	1.3	6
20	Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. European Urology Oncology, 2021, 4, 955-962.	2.6	14
21	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
22	PINâ€like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology, 2021, 78, 327-333.	1.6	9
23	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	0.8	6
24	CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer. Clinical Cancer Research, 2021, 27, 380-382.	3.2	10
25	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	1.9	33
26	Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. Journal of Pathology, 2021, 253, 415-426.	2.1	13
27	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Modern Pathology, 2021, 34, 1185-1193.	2.9	61
28	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	0.9	61
29	A distinct repertoire of <scp>cancerâ€associated</scp> fibroblasts is enriched in cribriform prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 271-286.	1.3	9
30	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature Communications, 2021, 12, 935.	5.8	56
31	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology, 2021, 80, 746-757.	0.9	50
32	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer, 2021, 147, 74-83.	1.3	42
33	A PRC2-independent function for EZH2 in regulating rRNA 2â€²-O methylation and IRES-dependent translation. Nature Cell Biology, 2021, 23, 341-354.	4.6	54
34	The somatic mutation landscape of germline CHEK2-altered prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5084-5084.	0.8	2
35	Mismatch repairâ€“deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade. Journal of Physical Education and Sports Management, 2021, 7, a006094.	0.5	4
36	Transcriptional landscape of PTEN loss in primary prostate cancer. BMC Cancer, 2021, 21, 856.	1.1	16

#	Article	IF	Citations
37	Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies. Journal of Molecular Diagnostics, 2021, 23, 1030-1041.	1.2	3
38	Reciprocal <scp>YAP1</scp> loss and <scp>INSM1</scp> expression in neuroendocrine prostate cancer. Journal of Pathology, 2021, 255, 425-437.	2.1	12
39	Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. Cancer Prevention Research, 2021, 14, 463-470.	0.7	3
40	Family history of prostate cancer and the incidence of ERGâ€•and phosphatase and tensin homologâ€defined prostate cancer. International Journal of Cancer, 2020, 146, 2694-2702.	2.3	3
41	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer, 2020, 126, 1407-1412.	2.0	8
42	The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. Advances in Anatomic Pathology, 2020, 27, 11-19.	2.4	12
43	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	3.2	35
44	Germline BLM mutations and metastatic prostate cancer. Prostate, 2020, 80, 235-237.	1.2	15
45	Genomic and Clinicopathologic Characterization ofATM-deficient Prostate Cancer. Clinical Cancer Research, 2020, 26, 4869-4881.	3.2	18
46	Neuroendocrine differentiation in usualâ€type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 2020, 80, 1012-1023.	1.2	22
47	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	5.8	76
48	Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e319-e332.	1.8	3
49	Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 676-680.	1.1	11
50	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332.	0.9	18
51	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	2.1	40
52	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). Journal of the National Cancer Institute, 2020, 112, 1098-1104.	3.0	21
53	CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. Clinical Cancer Research, 2020, 26, 2595-2602.	3.2	16
54	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology, 2020, 3, 224-230.	2.6	41

#	Article	IF	Citations
55	CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	1.5	138
56	High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 668-675.	1.1	16
57	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology, 2020, 101, 70-79.	1.1	5
58	PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy. Journal of Urology, 2020, 203, 344-350.	0.2	12
59	Association between BRCA2 status and histologic variants (intraductal [IDC] and cribriform [CRIB]) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	2
60	Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.. Journal of Clinical Oncology, 2020, 38, 63-63.	0.8	1
61	Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030403.	2.9	25
62	Genomic and clinical characterization of pulmonaryâ€only metastatic prostate cancer: A unique molecular subtype. Prostate, 2019, 79, 1572-1579.	1.2	23
63	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	3.2	200
64	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. International Journal of Cancer, 2019, 145, 3453-3461.	2.3	18
65	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	1.1	3
66	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research, 2019, 79, 3636-3650.	0.4	47
67	Intraductal carcinoma of the prostate in the absence of highâ€grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. Journal of Pathology, 2019, 249, 79-89.	2.1	44
68	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Human Pathology, 2019, 87, 95-102.	1.1	34
69	If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. Asian Journal of Urology, 2019, 6, 10-25.	0.5	20
70	SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy. Prostate Cancer and Prostatic Diseases, 2019, 22, 552-559.	2.0	13
71	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. JCO Precision Oncology, 2019, 3, 1-13.	1.5	12
72	Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. Oncologist, 2019, 24, 1526-1533.	1.9	39

#	Article	IF	Citations
73	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2047-2054.	1.1	11
74	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment NaÃ¯ve Primary Prostate Cancer. Clinical Cancer Research, 2019, 25, 6721-6730.	3.2	74
75	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology, 2019, 3, 1-9.	1.5	47
76	Mannose Receptorâ€“positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. European Urology Oncology, 2019, 2, 429-436.	2.6	46
77	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European Urology Oncology, 2019, 2, 405-412.	2.6	14
78	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer and Prostatic Diseases, 2019, 22, 59-65.	2.0	67
79	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 2019, 22, 399-405.	2.0	53
80	Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 338-348.	1.2	7
81	DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giantâ€cell features. Histopathology, 2019, 74, 836-843.	1.6	15
82	Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. European Urology, 2019, 75, 378-382.	0.9	137
83	PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 176-181.	2.0	13
84	Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy. Journal of Urology, 2019, 201, 937-942.	0.2	7
85	mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation. Journal of Clinical Investigation, 2019, 129, 5584-5599.	3.9	22
86	Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.. Journal of Clinical Oncology, 2019, 37, 5045-5045.	0.8	12
87	ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay.. Journal of Clinical Oncology, 2019, 37, 5069-5069.	0.8	3
88	Percent genome alteration and outcomes after radical prostatectomy in African American men.. Journal of Clinical Oncology, 2019, 37, 24-24.	0.8	0
89	SPINK1 expression and outcomes postprostatectomy in race-specific cohorts.. Journal of Clinical Oncology, 2019, 37, 23-23.	0.8	0
90	Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP).. Journal of Clinical Oncology, 2019, 37, 54-54.	0.8	0

#	Article	IF	Citations
91	WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2019, 37, 5068-5068.	0.8	0
92	Clinical outcomes and genomic analysis in patients with very high-risk clinically localized prostate cancer treated by radical prostatectomy.. Journal of Clinical Oncology, 2019, 37, 5067-5067.	0.8	0
93	Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 2018, 15, 222-234.	1.9	408
94	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational New Drugs, 2018, 36, 458-467.	1.2	61
95	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNAâ€repair gene mutations in prostate cancer. Prostate, 2018, 78, 401-407.	1.2	105
96	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 260-268.	2.0	48
97	The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer. European Urology, 2018, 74, 155-156.	0.9	0
98	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	1.9	119
99	Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features. American Journal of Surgical Pathology, 2018, 42, 1286-1296.	2.1	31
100	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clinical Cancer Research, 2018, 24, 3908-3916.	3.2	24
101	ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate, 2018, 78, 896-904.	1.2	13
102	Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Modern Pathology, 2018, 31, 1539-1552.	2.9	70
103	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience, 2018, 7, .	3.3	54
104	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncology, 2018, 84, 134-136.	0.8	4
105	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. , 2018, 6, 29.		96
106	PI3K/Akt/mTOR/PTEN and ERK/MAPK Pathways. Molecular Pathology Library, 2018, , 367-379.	0.1	2
107	Genomic characterization of ductal adenocarcinoma of the prostate.. Journal of Clinical Oncology, 2018, 36, 5030-5030.	0.8	1
108	Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: Implications for neoadjuvant clinical trial design.. Journal of Clinical Oncology, 2018, 36, 5062-5062.	0.8	2

#	Article	IF	Citations
109	Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).. Journal of Clinical Oncology, 2018, 36, TPS5095-TPS5095.	0.8	5
110	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. Journal of Urology, 2017, 197, 1245-1250.	0.2	16
111	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clinical Cancer Research, 2017, 23, 4693-4703.	3.2	62
112	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	0.9	79
113	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. Journal of Molecular Diagnostics, 2017, 19, 475-484.	1.2	16
114	AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nature Communications, 2017, 8, 142.	5.8	36
115	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	3.2	122
116	Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e65-e68.	0.9	61
117	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. European Urology, 2017, 71, 697-700.	0.9	65
118	PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy. Journal of Urology, 2017, 197, 1054-1059.	0.2	32
119	Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer, 2017, 17, 759.	1.1	57
120	mTORC1 loss impairs epidermal adhesion via TGF-Î²/Rho kinase activation. Journal of Clinical Investigation, 2017, 127, 4001-4017.	3.9	30
121	Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.. Journal of Clinical Oncology, 2017, 2017, 4-4.	0.8	1
122	Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget, 2017, 8, 22772-22782.	0.8	9
123	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget, 2017, 8, 65566-65576.	0.8	56
124	Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.. Journal of Clinical Oncology, 2017, 35, 4-4.	0.8	1
125	P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2017, 35, 5064-5064.	0.8	0
126	ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. Human Pathology, 2016, 55, 117-125.	1.1	36

#	Article	IF	Citations
127	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology, 2016, 29, 764-771.	2.9	53
128	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research, 2016, 22, 4651-4663.	3.2	34
129	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	2.9	71
130	Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (<scp>PIN</scp>) and intraductal carcinoma through retrograde glandular colonization. Journal of Pathology, 2016, 238, 31-41.	2.1	83
131	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	1.6	60
132	Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer. Urology Case Reports, 2016, 7, 64-66.	0.1	2
133	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 2016, 76, 125-139.	1.2	17
134	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. European Urology, 2016, 70, 14-17.	0.9	79
135	Premalignancy in Prostate Cancer: Rethinking What We Know. Cancer Prevention Research, 2016, 9, 648-656.	0.7	44
136	Development and validation of genomic signature to predict ADT treatment failure.. Journal of Clinical Oncology, 2016, 34, 5018-5018.	0.8	1
137	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.. Journal of Clinical Oncology, 2016, 34, 303-303.	0.8	2
138	Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.. Journal of Clinical Oncology, 2016, 34, 106-106.	0.8	0
139	The natural history and clinical/molecular characterization of primary Gleason pattern 5 (G5) prostate cancer (PCa) treated with radical prostatectomy (RP).. Journal of Clinical Oncology, 2016, 34, e16576-e16576.	0.8	0
140	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues.. Journal of Clinical Oncology, 2016, 34, 5055-5055.	0.8	0
141	PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate, 2015, 75, 1610-1619.	1.2	35
142	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 169-178.	2.1	99
143	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. Journal of the National Cancer Institute, 2015, 108, djv346.	3.0	149
144	Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. Human Pathology, 2015, 46, 554-557.	1.1	7

#	Article	IF	Citations
145	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	3.2	56
146	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 2015, 28, 128-137.	2.9	136
147	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	2.9	216
148	Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathology, 2015, 28, 446-456.	2.9	49
149	Î”Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Human Pathology, 2015, 46, 384-389.	1.1	13
150	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. American Journal of Surgical Pathology, 2014, 38, 756-767.	2.1	439
151	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	1.9	250
152	Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2014, 20, 890-903.	3.2	275
153	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine, 2014, 371, 1028-1038.	13.9	2,233
154	Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5001-5001.	0.8	20
155	Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 127-127.	0.8	2
156	Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.. Journal of Clinical Oncology, 2014, 32, 93-93.	0.8	0
157	Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Modern Pathology, 2013, 26, 587-603.	2.9	129
158	Prostatic Stromal Neoplasms: Differential Diagnosis of Cystic and Solid Prostatic and Periprostatic Masses. American Journal of Roentgenology, 2013, 200, W571-W580.	1.0	11
159	Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease. Cell Cycle, 2013, 12, 1835-1841.	1.3	23
160	mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss. Cancer Research, 2013, 73, 5218-5231.	0.4	13
161	Aberrant Expression of p63 in Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2013, 37, 1401-1406.	2.1	44
162	A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. American Journal of Clinical Pathology, 2013, 139, 151-159.	0.4	44

#	Article	IF	Citations
163	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer, 2012, 118, 6063-6071.	2.0	91
164	MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. International Journal of Cancer, 2012, 130, 509-520.	2.3	10
165	ERG gene rearrangements are common in prostatic small cell carcinomas. Modern Pathology, 2011, 24, 820-828.	2.9	191
166	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	1.9	423
167	PI3K/mTOR signaling regulates prostatic branching morphogenesis. Developmental Biology, 2011, 360, 329-342.	0.9	31
168	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2â€“ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	2.9	57
169	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 6563-6573.	3.2	309
170	In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clinical and Experimental Metastasis, 2010, 27, 185-196.	1.7	45
171	Clinical implications of changing definitions within the Gleason grading system. Nature Reviews Urology, 2010, 7, 136-142.	1.9	38
172	MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells. PLoS ONE, 2010, 5, e9427.	1.1	113
173	A case of gastrointestinal stromal tumor diagnosed on prostate biopsy. Nature Reviews Urology, 2009, 6, 54-57.	1.4	4
174	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 359-365.	2.9	51
175	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 1399-1400.	2.9	2
176	Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Human Pathology, 2009, 40, 471-477.	1.1	69
177	Small Endoscopic Biopsies of the Ureter and Renal Pelvis. American Journal of Surgical Pathology, 2009, 33, 1540-1546.	2.1	122
178	Immunohistochemical Panel to Identify the Primary Site of Invasive Micropapillary Carcinoma. American Journal of Surgical Pathology, 2009, 33, 1037-1041.	2.1	117
179	Recutting prostate needle core biopsies with high grade prostatic intraepithelial neoplasia increases detection of adenocarcinoma. Canadian Journal of Urology, 2009, 16, 4484-9.	0.0	4
180	Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer and Metastasis Reviews, 2008, 27, 67-73.	2.7	31

#	Article	IF	Citations
181	Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU International, 2008, 101, 366-370.	1.3	195
182	New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Letters, 2008, 272, 12-22.	3.2	21
183	c-Jun NH2-Terminal Kinase Activating Kinase 1/Mitogen-Activated Protein Kinase Kinase 4â€“Mediated Inhibition of SKOV3ip.1 Ovarian Cancer Metastasis Involves Growth Arrest and p21 Up-regulation. Cancer Research, 2008, 68, 2166-2175.	0.4	27
184	Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1360-1366.	2.1	23
185	Efficacy of the argon beam coagulator alone in obtaining hemostasis after laparoscopic porcine heminephrectomy: a pilot study. Canadian Journal of Urology, 2008, 15, 4091-6.	0.0	2
186	Assessment of the LapraTy Clip for Facilitating Reconstructive Laparoscopic Surgery in a Porcine Model. Urology, 2007, 69, 582-585.	0.5	17
187	Well-differentiated papillary mesothelioma occurring in the tunica vaginalis of the testis with contralateral atypical mesothelial hyperplasia. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 36-39.	0.8	42